Muhammad Erfan Uddin

机构：AbbVie (United States) · ORCID：0000-0002-7160-0455

发表论文 55 篇 · 总被引 535 次 · h-index 13

代表论文

Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy (2023 · JCI Insight · 被引 15)
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity (2022 · Cancer Research Communications · 被引 12)
Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2023 · Blood · 被引 3)
Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment (2025 · Clinical Pharmacokinetics · 被引 1)
Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (2024 · Blood)
Data from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity (2023)